The Nutritional Status of Chronic Obstructive Pulmonary Disease Exacerbators

Table 1

General characteristics of COPD patients.

All patients, n = 30
Gender, n (%)
Female	7 (23.3)
Male	23 (76.7)
Age, year, median (IQR)	68 (11)
Tobaco (pack-year)	50.8 ± 22.8
Smoking status, n (%)
Current smokers	13 (43.3)
Ex-smokers	16 (53.3)
Never smokers	1 (3.3)
GOLD, n (%)
A	1 (3.3)
B	7 (23.3)
C	0
D	22 (73.3)
Obstruction, n (%)
FEV1 ≥ 80%	0
FEV1 ≥ 50%	11 (36.7)
FEV1 ≥ 30%	13 (43.3)
FEV1 < 30%.	6 (20)
Bronchodilator therapy, n (%)
LAMA + LABA	6 (20)
LAMA + LABA + ICS	24 (60)
Home non-invasive ventilation, n (%)	12 (40)
Home oxygen therapy, n (%)	20 (66.7)
Comorbidity, n (%)
Hypertension	24 (80.0)
Diabetes	9 (30.0)
Dyslipidemia	18 (60.0)
Auricular fibrillation	7 (23.3)
Ischemic heart disease	9 (30.0)
Tuberculosis sequelae	5 (16.7)
Gastroesophageal reflux disease	5 (16.7)
Anxiety	5 (16.7)
Depression	4 (13.3)
Enphysema	19 (63.3)
Height, cm, median (IQR)	163 (6.50)
Weight, kg, mean ± SD	61.6 ± 19.6
BMI, Kg/m^2, mean ± SD	22.7 ± 7.9
BMI, n (%)
<18.5 Kg/m^2	11 (36.7)
18.5–25 kg/m^2	5 (16.7)
25–30 kg/m^2	7 (23.3)
>30 kg/m^2	7 (23.3)
NRS-2002, n (%)
1	6 (20.0)
2	9 (30.0)
3	9 (30.0)
4	3 (10.0)
5	3 (10.0)
Albumin, g/L, median (IQR)	3.8 (0.8)
Total proteins, mean ± SD	6.0 ± 0.6
Vitamin D, ng/mL, mean ± SD	8.3 ± 2.6
MUAC, cm, mean ± SD	23.5 ± 7.2
TST, mm, mean ± SD	7.6 ± 4.2

LAMA: long-acting muscarinic antagonist; LABA: long-acting beta2-agonist; ICS: inhaled corticosteroids; BMI: body mass index; MUAC: midupper arm circumference; TST: tricipital skinfold thickness.